JAAD Game Changers: Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Pyoderma gangrenosum is a painful ulcerating disease. The current evidence base for treatment is limited. In a large prospective study of topical treatments, 44% of patients were healed by 6 months. Ulcer size was a predictor of healing, and 15% of patients with pyoderma gangrenosum had a recurrence...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of the American Academy of Dermatology Vol. 80; no. 4; pp. 1178 - 1179
Autor principal: Lake, Eden
Formato: commentary Journal Article
Publicado: Elsevier B.V. Apr2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135293575&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 135293575
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01909622
        1ZF
      jtl: Journal of the American Academy of Dermatology
      issn: 01909622
      maglogo: N
    pubinfo:
      dt: Apr2019
      vid: 80
      iid: 4
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        135293575
        135293575
        NLM30447323
        135293575
        10.1016/j.jaad.2018.11.003
        NLM30447323
        135293575
      ppf: 1178
      ppct: 1
      formats:
      tig:
        atl: JAAD Game Changers: Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.
      aug:
        au: Lake, Eden
        affil: Maywood, Illinois
      sug:
        subj:
          Pyoderma Gangrenosum
          Prospective Studies
          Scales
      ab: Pyoderma gangrenosum is a painful ulcerating disease. The current evidence base for treatment is limited. In a large prospective study of topical treatments, 44% of patients were healed by 6 months. Ulcer size was a predictor of healing, and 15% of patients with pyoderma gangrenosum had a recurrence. Clobetasol propionate 0.05% is a potentially useful first-line therapy for patients with pyoderma gangrenosum, particularly for patients with small lesions.
      pubtype: Academic Journal
      doctype:
        commentary
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N